UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~April 230, 2008

SCIELE PHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-30123	58-2004779
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Five Concourse Parkway

Suite 1800 Atlanta, Georgia 30328

Atlanta, Georgia 30328

(Address of principal executive offices) (Zip Code)

~~Registrant’s telephone number, including area code:~~ (770) 442-9707

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act o Soliciting material pursuant to Rule 14a-12 under the Exchange Act o Pre-commencement communications pursuant to Rule 14d-2(~~b) under~~Registrant’s ~~the~~telephone ~~Exchange~~number, ~~Act o Pre-commencement~~including ~~communications~~area ~~pursuant to Rule 13e-4(c~~code) ~~under the Exchange Act~~

~~Item~~Check the appropriate box below if the Form 8~~.01~~-K ~~Other~~filing ~~Events~~is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Ono ~~January 2,~~Written ~~2008,~~communications ~~Sciele~~pursuant ~~Pharma, Inc. (the~~to ~~“Company”)~~Rule ~~announced~~425 under the ~~U.S.~~Securities ~~Food & Drug~~Act ~~Administration~~o ~~(FDA)~~Soliciting ~~has~~material ~~approved~~pursuant ~~all~~to ~~four~~Rule ~~dosage~~14a-12 ~~strengths~~under of the ~~new Sular®~~Exchange ~~formulation. The~~Act ~~Sular® formulation,~~o ~~which~~Pre-commencement ~~utilizes~~communications ~~SkyePharma’s~~pursuant to Rule 14d-2(~~LSE:SKP~~b) ~~patented~~under ~~GEOMATRIX™ technology,~~the ~~provides~~Exchange aAct ~~lower~~o ~~dose~~Pre-commencement ofcommunications ~~Sular®~~pursuant ~~for each of its current doses. The Company expects~~ to ~~launch~~Rule ~~the~~13e-4(c) ~~new~~under ~~Sular® formulation during~~ the ~~first~~Exchange ~~quarter of 2008. A copy of the press release is attached to this Report as Exhibit 99.1~~Act

Item 2.02 Results of Operations and Financial Condition

On April 30, 2008, Sciele Pharma, Inc. issued a press release announcing its results for the fiscal quarter ended March 31, 2008. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

99(d) Exhibits.~~1 Press release dated January 2, 2008.~~

Exhibit 99.1 Press release issued by Sciele Pharma, Inc. on April 30, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCIELE PHARMA, INC. (Registrant) By: /s/ Darrell Borne Name: Darrell Borne Title: EVP, Chief Financial Officer, Secretary and Treasurer

	Sciele Pharma, Inc.
	(Registrant)

	By:	/s/ Darrell Borne
		Darrell Borne
		Executive Vice President, Chief Financial
		Officer, Secretary and Treasurer

Date: April 30, 2008

~~Date: January 4, 2008~~3

Exhibits

Exhibit No.		Description

99.1		Press release issued by Sciele Pharma, Inc. on April 30, 2008.

Filing Compare · SCIELE PHARMA, INC.